Posted inDermatology news
Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid
A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, supporting further randomized evaluation.